Streetbeat News

Earnings

AXSM

Axsome Therapeutics reported its Q4 earnings, showing rising revenues. However, skepticism remains among investors.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

ICCC

ImmuCell is set to announce its unaudited financial results for Q4 and the full year ending December 31, 2024. A conference call is scheduled for February 26, 2025, at 9:00 AM ET.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

BMBL

Bumble's stock has faced significant challenges in 2024, with its price dropping below $5/share following poor Q2 results. The company is experiencing revenue declines in Q4 and expects reduced profitability in 2025. Additionally, Bumble failed to provide a complete audited set of financial results, adding uncertainty.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

INDV

Indivior PLC (INDV) reported Q4 earnings of $0.32 per share, matching the Zacks Consensus Estimate but down from $0.43 per share a year ago.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

MD

Pediatrix Medical Group (MD) reported Q4 earnings of $0.51 per share, surpassing the Zacks Consensus Estimate of $0.37. This marks an improvement from $0.32 per share a year ago.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

EPAM

Epam (EPAM) reported Q4 earnings of $2.84 per share, surpassing the Zacks Consensus Estimate of $2.75. This marks an improvement from the $2.75 per share reported a year ago.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

WMT

Walmart's stock is experiencing a decline as the company forecasts a drop in earnings for the first time in three years. Despite expecting consumer stability, Walmart anticipates continued pressure on its product mix.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

TECK

Teck Resources Ltd (TECK) reported Q4 earnings of $0.33 per share, surpassing the Zacks Consensus Estimate of $0.22. This is a decrease from $1.02 per share a year ago.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

BIRK

Birkenstock (BIRK) reported Q1 earnings of $0.19 per share, surpassing the Zacks Consensus Estimate of $0.16. This marks a significant improvement from $0.09 per share a year ago.

Portfolio Pulse from

February 20, 2025 | 1:30 pm

BTCY

Biotricity Inc. reported record margins, revenues, and cashflows for Q3 of fiscal 2025, with a 21.7% year-over-year sales growth. The company is a leader in Technology-as-a-Service for healthcare.

Portfolio Pulse from

February 20, 2025 | 1:30 pm